

# Camilla Krakstad

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2478428/camilla-krakstad-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124  
papers

4,230  
citations

31  
h-index

62  
g-index

139  
ext. papers

5,119  
ext. citations

7.1  
avg. IF

4.65  
L-index

#	Paper	IF	Citations
124	MRI-assessed tumor-free distance to serosa predicts deep myometrial invasion and poor outcome in endometrial cancer.. <i>Insights Into Imaging</i> , <b>2022</b> , 13, 1	5.6	3
123	Interobserver agreement and prognostic impact for MRI-based 2018 FIGO staging parameters in uterine cervical cancer.. <i>European Radiology</i> , <b>2022</b> , 1	8	0
122	Fully Automatic Whole-Volume Tumor Segmentation in Cervical Cancer. <i>Cancers</i> , <b>2022</b> , 14, 2372	6.6	0
121	Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
120	Genomic alterations associated with mutational signatures, DNA damage repair and chromatin remodeling pathways in cervical carcinoma. <i>Npj Genomic Medicine</i> , <b>2021</b> , 6, 82	6.2	1
119	A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 1690-1698	8.7	5
118	Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , <b>2021</b> , 225, 407.e1-407.e16	6.4	2
117	Incorporating molecular profiling into endometrial cancer management requires prospective studies. <i>International Journal of Gynecological Cancer</i> , <b>2021</b> , 31, 944-945	3.5	2
116	Cancer awareness in the general population varies with sex, age and media coverage: A population-based survey with focus on gynecologic cancers. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , <b>2021</b> , 256, 25-31	2.4	0
115	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 307-319	7.5	13
114	Whole-Volume Tumor MRI Radiomics for Prognostic Modeling in Endometrial Cancer. <i>Journal of Magnetic Resonance Imaging</i> , <b>2021</b> , 53, 928-937	5.6	15
113	Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer. <i>Gynecologic Oncology</i> , <b>2021</b> , 160, 396-404	4.9	1
112	The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. <i>Human Pathology</i> , <b>2021</b> , 109, 80-91	3.7	8
111	Automated segmentation of endometrial cancer on MR images using deep learning. <i>Scientific Reports</i> , <b>2021</b> , 11, 179	4.9	7
110	Nuclear upregulation of class I phosphoinositide 3-kinase p110 $\alpha$ correlates with high 47S rRNA levels in cancer cells. <i>Journal of Cell Science</i> , <b>2021</b> , 134,	5.3	3
109	An MRI-Based Radiomic Prognostic Index Predicts Poor Outcome and Specific Genetic Alterations in Endometrial Cancer. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3
108	Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. <i>Human Genetics</i> , <b>2021</b> , 140, 1353-1365	6.3	5

107	Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis. <i>Communications Medicine</i> , <b>2021</b> , 1,		2
106	Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: a prospective cohort study. <i>American Journal of Obstetrics and Gynecology</i> , <b>2021</b> ,	6.4	2
105	Feasibility and utility of MRI and dynamic F-FDG-PET in an orthotopic organoid-based patient-derived mouse model of endometrial cancer. <i>Journal of Translational Medicine</i> , <b>2021</b> , 19, 406	8.5	0
104	Genomic Characterization and Therapeutic Targeting of HPV Undetected Cervical Carcinomas. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
103	High-Grade Cervical Intraepithelial Neoplasia (CIN) Associates with Increased Proliferation and Attenuated Immune Signaling.. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 23,	6.3	4
102	A radiogenomics application for prognostic profiling of endometrial cancer. <i>Communications Biology</i> , <b>2021</b> , 4, 1363	6.7	1
101	Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003111	11.6	6
100	Improving response to progestin treatment of low-grade endometrial cancer. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 1811-1823	3.5	8
99	Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer. <i>European Radiology</i> , <b>2020</b> , 30, 2443-2453	8	7
98	Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 1014-1022	8.7	2
97	High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. <i>Gynecologic Oncology</i> , <b>2020</b> , 157, 260-267	4.9	14
96	Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7
95	Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling. <i>Gynecologic Oncology</i> , <b>2020</b> , 156, 400-406	4.9	5
94	Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer. <i>PLoS ONE</i> , <b>2019</b> , 14, e0210585	3.7	6
93	Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. <i>Human Pathology</i> , <b>2019</b> , 89, 90-98	3.7	2
92	Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of. <i>Cancer &amp; Metabolism</i> , <b>2019</b> , 7, 6	5.4	33
91	Impact of body mass index and fat distribution on sex steroid levels in endometrial carcinoma: a retrospective study. <i>BMC Cancer</i> , <b>2019</b> , 19, 547	4.8	9
90	Poor outcome in hypoxic endometrial carcinoma is related to vascular density. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 1037-1044	8.7	4

89	Blood Metabolites Associate with Prognosis in Endometrial Cancer. <i>Metabolites</i> , <b>2019</b> , 9,	5.6	6
88	Imaging of Preclinical Endometrial Cancer Models for Monitoring Tumor Progression and Response to Targeted Therapy. <i>Cancers</i> , <b>2019</b> , 11,	6.6	3
87	Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 334-345	12.9	9
86	Blood steroids are associated with prognosis and fat distribution in endometrial cancer. <i>Gynecologic Oncology</i> , <b>2019</b> , 152, 46-52	4.9	6
85	Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. <i>Cancer Medicine</i> , <b>2018</b> , 7, 1978-1987	4.8	40
84	In vivo MR spectroscopy predicts high tumor grade in endometrial cancer. <i>Acta Radiologica</i> , <b>2018</b> , 59, 497-505	2	5
83	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. <i>PLoS ONE</i> , <b>2018</b> , 13, e0197561	3.7	9
82	Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2018</b> , 125, 1695-1703	3.7	4
81	Identification of nine new susceptibility loci for endometrial cancer. <i>Nature Communications</i> , <b>2018</b> , 9, 3166	17.4	70
80	Patient-Derived Xenograft Models for Endometrial Cancer Research. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	18
79	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	3
78	Preoperative tumor texture analysis on MRI predicts high-risk disease and reduced survival in endometrial cancer. <i>Journal of Magnetic Resonance Imaging</i> , <b>2018</b> , 48, 1637-1647	5.6	57
77	HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 378-387	8.7	24
76	Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions. <i>Gynecologic Oncology</i> , <b>2018</b> , 148, 197-203	4.9	12
75	Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. <i>Acta Radiologica</i> , <b>2018</b> , 59, 1010-1017	2	27
74	Blocking 17 $\beta$ hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach. <i>Journal of Pathology</i> , <b>2018</b> , 244, 203-214	9.4	15
73	The prognostic value of preoperative FDG-PET/CT metabolic parameters in cervical cancer patients. <i>European Journal of Hybrid Imaging</i> , <b>2018</b> , 2,	1.7	7
72	Class I Phosphoinositide 3-Kinase /p110 $\alpha$ and /p110 $\beta$ isoforms in Endometrial Cancer. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	10

71	Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. <i>PLoS ONE</i> , <b>2018</b> , 13, e0206665	3.7	9
70	Development of an Image-Guided Orthotopic Xenograft Mouse Model of Endometrial Cancer with Controllable Estrogen Exposure. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	5
69	High mRNA levels of 17 $\beta$ hydroxysteroid dehydrogenase type 1 correlate with poor prognosis in endometrial cancer. <i>Molecular and Cellular Endocrinology</i> , <b>2017</b> , 442, 51-57	4.4	20
68	Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. <i>Gynecologic Oncology</i> , <b>2017</b> , 147, 672-677	4.9	10
67	Type of vascular invasion in association with progress of endometrial cancer. <i>Apmis</i> , <b>2017</b> , 125, 1084-1091	3.4	4
66	PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. <i>Scientific Reports</i> , <b>2017</b> , 7, 10240	4.9	14
65	Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 840-847	8.7	22
64	Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. <i>American Journal of Obstetrics and Gynecology</i> , <b>2017</b> , 217, 432.e1-432.e17	6.4	23
63	Endometrial cancer cells exhibit high expression of p110 $\alpha$ and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. <i>Oncotarget</i> , <b>2017</b> , 8, 3881-3894	3.3	10
62	Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. <i>Oncotarget</i> , <b>2017</b> , 8, 9696-9707	3.3	3
61	Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. <i>Oncotarget</i> , <b>2017</b> , 8, 68530-68541	3.3	5
60	High visceral fat percentage is associated with poor outcome in endometrial cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 105184-105195	3.3	22
59	Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. <i>Oncotarget</i> , <b>2017</b> , 8, 106989-107001	3.3	7
58	Tumour-microenvironmental blood flow determines a metabolomic signature identifying lysophospholipids and resolvin D as biomarkers in endometrial cancer patients. <i>Oncotarget</i> , <b>2017</b> , 8, 109018-109026	3.3	10
57	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , <b>2016</b> , 141, 386-401	4.9	15
56	The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. <i>Nature Genetics</i> , <b>2016</b> , 48, 848-55	36.3	135
55	Evidence of a genetic link between endometriosis and ovarian cancer. <i>Fertility and Sterility</i> , <b>2016</b> , 105, 35-43.e1-10	4.8	26
54	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 69097-69110	3.3	4

53	Androgen receptor as potential therapeutic target in metastatic endometrial cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 49289-49298	3.3	36
52	Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 69844-69856	3.3	20
51	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , <b>2015</b> , 47, 164-71	36.3	177
50	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2015</b> , 24, 1574-84	4	24
49	Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma. <i>Gynecologic Oncology</i> , <b>2015</b> , 137, 529-37	4.9	17
48	PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. <i>Molecular Oncology</i> , <b>2015</b> , 9, 1694-703	7.9	40
47	Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. <i>Gynecologic Oncology</i> , <b>2015</b> , 136, 542-8	4.9	12
46	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. <i>Nature Communications</i> , <b>2015</b> , 6, 8234	17.4	40
45	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , <b>2015</b> , 36, 1341-53	4.6	20
44	Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. <i>International Journal of Cancer</i> , <b>2015</b> , 136, 1863-73	7.5	30
43	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , <b>2015</b> , 39, 689-97	2.6	18
42	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , <b>2015</b> , 10, e0128106	3.7	15
41	Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma. <i>PLoS ONE</i> , <b>2015</b> , 10, e0135229	3.9	26
40	ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma. <i>Oncotarget</i> , <b>2015</b> , 6, 28440-52	3.3	29
39	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 3595-607	5.6	32
38	Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. <i>Oncotarget</i> , <b>2015</b> , 6, 1327-39	3.3	42
37	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). <i>Journal of Genetics and Genome Research</i> , <b>2015</b> , 2,		22
36	Landscape of genomic alterations in cervical carcinomas. <i>Nature</i> , <b>2014</b> , 506, 371-5	50.4	541

35	Molecular profiling in fresh tissue with high tumor cell content promotes enrichment for aggressive adenocarcinomas in cervix. <i>Pathology Research and Practice</i> , <b>2014</b> , 210, 774-8	3.4	
34	Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 3003-10	7.5	55
33	Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. <i>Molecular Nutrition and Food Research</i> , <b>2014</b> , 58, 2023-35	5.9	8
32	Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer. <i>PLoS ONE</i> , <b>2014</b> , 9, e90141	3.7	31
31	Introduction of aromatic ring-containing substituents in cyclic nucleotides is associated with inhibition of toxin uptake by the hepatocyte transporters OATP 1B1 and 1B3. <i>PLoS ONE</i> , <b>2014</b> , 9, e94926	3.7	7
30	Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. <i>Molecular Cancer</i> , <b>2014</b> , 13, 223	42.1	72
29	Risk of ovarian cancer and the NF- $\kappa$ B pathway: genetic association with IL1A and TNFSF10. <i>Cancer Research</i> , <b>2014</b> , 74, 852-61	10.1	36
28	Switch in FOXA1 status associates with endometrial cancer progression. <i>PLoS ONE</i> , <b>2014</b> , 9, e98069	3.7	21
27	Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. <i>Oncotarget</i> , <b>2014</b> , 5, 1052-61	3.3	25
26	Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 3431-41	7.5	95
25	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , <b>2013</b> , 45, 362-70, 370e1-2	36.3	267
24	Off-target effect of the Epac agonist 8-pCPT-2FO-Me-cAMP on P2Y12 receptors in blood platelets. <i>Biochemical and Biophysical Research Communications</i> , <b>2013</b> , 437, 603-8	3.4	14
23	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , <b>2013</b> , 45, 371-84, 384e1-2	36.3	422
22	Lack of estrogen receptor- $\beta$ s associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 1094-105	12.9	110
21	ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. <i>Modern Pathology</i> , <b>2013</b> , 26, 428-34	9.8	47
20	Polymorphisms in inflammation pathway genes and endometrial cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2013</b> , 22, 216-23	4	22
19	High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 2331-41	12.9	33
18	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , <b>2013</b> , 4, 1628	17.4	124

17	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , <b>2013</b> , 4, 1627	17.4	85
16	Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. <i>PLoS ONE</i> , <b>2013</b> , 8, e54873	3.7	56
15	PI3K pathway in gynecologic malignancies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2013</b> ,	7.1	12
14	Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2012</b> , 21, 980-7	4	30
13	Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas. <i>Histopathology</i> , <b>2012</b> , 60, 516-9	7.3	5
12	Loss of GPER identifies new targets for therapy among a subgroup of ER $\alpha$ -positive endometrial cancer patients with poor outcome. <i>British Journal of Cancer</i> , <b>2012</b> , 106, 1682-8	8.7	47
11	High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. <i>PLoS ONE</i> , <b>2012</b> , 7, e52795	3.7	30
10	Nostocyclopeptide-M1: a potent, nontoxic inhibitor of the hepatocyte drug transporters OATP1B3 and OATP1B1. <i>Molecular Pharmaceutics</i> , <b>2011</b> , 8, 360-7	5.6	24
9	The cAMP-dependent protein kinase pathway as therapeutic target: possibilities and pitfalls. <i>Current Topics in Medicinal Chemistry</i> , <b>2011</b> , 11, 1393-405	3	15
8	Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. <i>Molecular Cancer</i> , <b>2010</b> , 9, 135	42.1	203
7	Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. <i>Blood</i> , <b>2008</b> , 111, 2866-77	2.2	31
6	Serine/Threonine Protein Phosphatases in Apoptosis <b>2006</b> , 151-166		2
5	cAMP protects neutrophils against TNF-alpha-induced apoptosis by activation of cAMP-dependent protein kinase, independently of exchange protein directly activated by cAMP (Epac). <i>Journal of Leukocyte Biology</i> , <b>2004</b> , 76, 641-7	6.5	40
4	Mitochondrial-targeted fatty acid analog induces apoptosis with selective loss of mitochondrial glutathione in promyelocytic leukemia cells. <i>Chemistry and Biology</i> , <b>2003</b> , 10, 609-18		18
3	cAMP effector mechanisms. Novel twists for an old signaling system. <i>FEBS Letters</i> , <b>2003</b> , 546, 121-6	3.8	150
2	Ca <sup>2+</sup> /calmodulin-dependent protein kinase II is required for microcystin-induced apoptosis. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 2804-11	5.4	93
1	Combining genome-wide studies of breast, prostate, ovarian and endometrial cancers maps cross-cancer susceptibility loci and identifies new genetic associations		2